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ABSTRACT: The purpose of this study was to investigate the anti-inflammatory effect of platelet-rich plasma (PRP) with collagen matrix
on human nucleus pulposus (NP) cell in response to pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-a) and
interleukin-1 (IL-1). NP cells from human disks were cultured in a monolayer and maintained in the collagen matrix prior to the
addition of recombinant human IL-1 and TNF-a. After applying IL-1 and TNF-a, PRP prepared by using a commercially available
platelet concentration system was added. The response was investigated using real-time PCR for mRNA expression of type II collagen,
aggrecan, matrix metalloproteinase-3 (MMP-3), and cyclooxygenase-2 (COX-2). The combination of IL-1b and TNF-a led to decrease of
matrix synthesis gene expression such as collagen type II and aggrecan and increase of the degradation gene expression of COX-2 and
MMP-3, compared to the control. Consecutive PRP exposure significantly recovered the down-regulated gene expression of collagen type
II and aggrecan and significantly reduced the increased MMP-3 and COX-2 gene expression, compared to that of control groups with
pro-inflammatory cytokines. The administration of PRP with collagen matrix markedly suppressed cytokine-induced pro-inflammatory
degrading enzymes and mediators in the NP cell. It also rescued gene expression concerning matrix synthesis, thereby stabilizing NP
cell differentiation.  2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:551–556, 2014.
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Degenerative changes in human beings are an inevi-
table phenomenon.1 Many kinds of musculoskeletal
disorders are related to the degeneration of corre-
sponding tissue.2 Intervertebral disk (IVD) degenera-
tion plays a critical role in almost all lumbar diseases
including disk herniation, radiculopathy, spinal ste-
nosis, and low back pain.3–5 Alterations in the
extracellular matrix of the nucleus pulposus (NP) of
degenerated IVDs originate from marked decreases in
proteoglycan synthesis, increased aggrecan fragment
accumulation, decreased type II collagen synthesis,
and increased type I collagen synthesis. These factors
represent the major pathogenic characterization of
IVD degeneration.5–8
Furthermore, a variety of inflammatory mediators
have been implicated in IVD degeneration, including
nitric oxide (NO), interleukin-1 (IL-1), matrix metal-
loproteinases (MMP), prostaglandin E2 (PGE2), tumor
necrosis factor alpha (TNF-a), and a group of cyto-
kines.9,10 The cytokines IL-1and TNF-a are overex-
pressed in degenerated IVD, which has led to both
being implicated in the matrix degradation that char-
acterizes disk degeneration.11–13 There is some direct
evidence that both IL-1 and TNF-a might be involved
in matrix degradation.10,14,15
Platelet-rich plasma (PRP) is extracted from whole
blood and contains mixed growth factors such as
tumor growth factor-b (TGF-b), vascular epithelial
growth factor, platelet derived growth factor (PDGF),
and insulin-like growth factor (IGF), which has been
used for soft tissue and bone repair in several clinical
settings.16–19 Concerning IVD, a previous study have
demonstrated the potential of PRP on human IVD
cells, including promoting cell proliferation, and the
redifferentiation and reconstitution of human NP
tissue.20 Moreover, recent reports showed that PRP
modulated by collagen matrix has anti-inflammatory
potential to rescue the chondrocyte degeneration in-
duced by pro-inflammatory cytokines such as IL-1 and
TNF-a.21,22 Therefore, given that the IL-1 and TNF-a
also have a critical role in the degeneration of IVD as
pro-inflammatory cytokines, we hypothesized that
PRP might react with pro-inflammatory cytokine to
maintain the homeostasis of NP cell. The purpose of
this study was to investigate the anti-inflammatory
effects of PRP with collagen matrix on human NP cells
responded to pro-inflammatory cytokines.
MATERIALS AND METHODS
All procedures were approved by institutional review board
at the hospital.
Nucleus Pulposus Cell Isolation and Culture
After a diagnosis of degenerative disk disease, such as
lumbar spinal stenosis or spondylolisthesis, disk tissues were
harvested from three patients (age 52–62 years, mean age;
58.1 years) at the time of surgery. The disks were classified
as grade 3 disk degeneration according to the Thompson
scale.23 The NP was dissected, washed with Hank’s balanced
salt solution (HBSS), and transported to the laboratory
within 30min. Specimens from individual patients were
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minced into small fragments. Cells (hNP) were then isolated
and expanded in monolayer with collagen matrix. The cells
were cultured in F-12/D-MEM containing 1% fetal bovine
serum (FBS), 1% penicillin–streptomycin (PS), and 25mg/ml
L-ascorbic acid under standard conditions (37˚C, 5% CO2,
95% air, bicarbonate buffering to maintain pH 7.2). Cell
culture materials were purchased from Introgen/Gibco
(Seoul, Korea) unless noted otherwise, and hNP cells were
used at passage 1 or 2. Experiments began after the cells
had been in monolayer culture for at least 1 week, when
collagen II mRNA expression had been restored, and after
culture in serum free medium with insulin–transferrin–
selenium for 24h.
PRP Preparation
Blood samples from three healthy donors were collected after
participants gave informed consent. PRP was prepared by
means of a GPS III System (Biomet, Inc., Warsaw, IN)
according to the manufacturer’s protocol. Upon addition of
22.8mM CaCl2 1:10 (v/v), clotting caused activated platelets
to release growth factors. Supernatant was collected, which
was assigned to PRP releasate. The baseline platelet and
white blood cell concentrations of whole blood and PRP
releasate were measured on a clinical ADVIA2120 (SIMENS,
Ireland, UK). PRP releasate was subsequently stored in
aliquots of 1.5ml at 80˚C for further experiments and
growth factor analyses. Baseline PDGF-AB was measured
using the PDGF-AB Quantikine ELISA Kit (R&D Systems,
Minneapolis, MN), while TGF-b1 was measured using
human TGF-b1 Immunoassay Quantikine (R&D Systems,
Abingdon, UK). Two sample dilutions were measured for
growth factor analyses.
PRP-Conditional Medium Preparation and Responses to Cytokines
NP cells were seeded into 24-well plates at a density of 2
104 cells/ml and treated with or without PRP, while the
experimental controls were cultured in F-12/DMEM supple-
mented with 1% FBS. As positive control, cells were treated
with PRP without pro-inflammatory cytokines. Cells were
then pre-treated with IL-1b (1.0ng/ml) and TNF-a (2.0 ng/ml)
for 48h which represented degenerative disk environment as
negative control, followed by PRP releasate (5%, 10%) for
48h. The optimum concentrations of IL-1b, TNF-a, and PRP
releasate were selected based on results obtained from
cytotoxicity studies using a broad concentration range for
each reagent.21,24,25
Gene Expression
Gene expression was analyzed by real-time RT-PCR using an
ABI PRISM1 7900HT, Sequence Detection System (Applied
Biosystems, Foster City, CA). The reactions were performed
with primers and tested to ensure specificity with melt curve
analysis performed with each assay (Table 1). Type II
collagen and aggrecan were analyzed to assess matrix gene
expressions, while the cyclooxygenase-2 (COX-2) and MMP-3
genes were analyzed to assess inflammatory reactions and
matrix degradation, respectively. Real-time RT-PCR reac-
tions were performed in duplicate in 96-well plates in a
volume of 25ml using the reagents and optimized protocol of
the VeriQuest SYBR Green qPCR Master Mix (Affymetris,
Santa Clara, CA). Cycle threshold (Ct) values were obtained,
and the data were normalized to GAPDH expression using
the DDCt method to calculate relative mRNA levels for each
gene.
Statistical Analysis
All values were reported as the mean standard deviation of
the analysis results of separate cultures. Experiments were
performed for three PRP donors on each NP cell donor.
Statistical analysis was performed using a mixed-model
analysis of variance. The treatment was considered as a fixed
factor, and donor was considered as a random factor. The
post hoc analysis was also used. The effects of IL-1b/TNF-a,
and/or PRP were calculated in separate models. A p value
<0.05 was considered statistically significant. All statistical
analyses were performed by using the SPSS 20.0.0 statistics
package (SPSS, Inc., Chicago, IL).
RESULTS
White Blood–Cell Concentration and Baseline Analysis of
Growth Factors in PRP
The mean white blood cell and platelet concentration
in the whole blood samples were 5.31.4 103/ml and
198.4 54.2103/ml, respectively. On average, PRP
had a platelet concentration 3.9 times higher (773.8
156.43 103/ml) than that of whole blood and con-
tained more white blood cells (15.816.3 103/ml;
Table 2). The growth factors PDGF-AB and TGF-1b
were abundantly present in PRP releasate (Table 2).
Effects of Pro-Inflammatory Cytokines on NP Cell Gene
Expression
The combination of IL-1b (1.0 ng/ml) and TNF-a
(2.0 ng/ml) led to decrease of matrix synthesis gene
expression, such as collagen type II and aggrecan,
more than the control. Contrarily, these cytokines
increased the degradation gene expression of COX-2
and MMP-3 compared to the control (Fig. 1). Among
these changes of gene expressions, however, COX-2
gene expression only demonstrated a statistically
significant increase compared to the control (Fig. 1).
Table 1. Primers Used for RT-PCR Analysis of Gene Expression
Gene 50 Forward 30 50 Reverse 30
GAPDH ACCCACTCCTCCACCTTTGAC TCCACCACCCTGTTGCTGTAG
Aggrecan AAGAATCAAGTGGAGCCGTGTGTC TGAGACCTTGTCCTGATAGGCACT
Type II collagen ATGACAATCTGGCTCCCAAC GAACCTGCTATTGCCCTC
MMP-3 CAAGGAGGCAGGCAAGACAGC GCCACGCACAGCAACAGTAGG
COX-2 TCCACCAACTTACAATGCTGACTATG AATCATCAGGCACAGGAGGAAGG
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Changes in other gene expressions after the adminis-
tration of pro-inflammatory cytokines were not sta-
tistically significant.
Effects of PRP on NP Cell Gene Expression
Exposing the control group to PRP caused only
statistically nonsignificant increases in matrix gene
expression of type II collagen and aggrecan compared
to the values of the control group without pro-inflam-
matory cytokines (Fig. 1). Expression of the inflamma-
tory COX-2 gene decreased after PRP administration,
but not in a statistically significant manner. However,
PRP significantly decreased MMP-3 gene expression
from the control without pro-inflammatory cytokines
(Fig. 1).
Retrieving Effect of PRP Against Pro-Inflammatory
Cytokines on NP Cell Gene Expression
PRP exposure significantly recovered the down-regu-
lated gene expression of collagen type II and aggrecan,
compared to control groups with pro-inflammatory
cytokines (Fig. 1). Conversely, PRP significantly re-
duced the increased MMP-3 gene expression, com-
pared to that of control groups with pro-inflammatory
cytokines. Furthermore, COX-2 gene expression signif-
icantly decreased in the PRP administration, com-
pared to the control group with pro-inflammatory
cytokines (Fig. 1).
DISCUSSION
Clinical evidence suggests that PRP could have benefi-
cial therapeutic effects on hard and soft tissue healing,
due to growth factors stored in the platelets.18,26 More-
over, previous studies reported an anti-inflammatory
role of activated PRP.21,26 This work was intended to
investigate both the retrieving and regenerative poten-
tials of PRP on NP cells against pro-inflammatory
cytokines such as TNF-a and IL-1.
As expected, our data demonstrated that a combina-
tion of IL-1b (1.0 ng/ml) and TNF-a (2.0 ng/ml) induced
degenerative changes in NP cells. These changes
included decreased expression of genes regarding
matrix synthesis such as collagen type II and aggrecan
and the increase expression of degradation genes such
as COX-2 and MMP-3. TNF-a and IL-1 are well
known as major pro-inflammatory cytokines. The NP
Table 2. Analyses of White Blood Cell Concentration





Whole blood 198.4 54.2 5.3 1.4
PRPr 773.8 156.43 15.81 6.3
PDGF-AB/BB TGF-b1
PRP releasate analyses (pg/ml)
Growth factors
(meanSD)
15,623.4 4,584.3 54,028.7 6,520.7
Values are meanSD. SD, standard deviation.
Figure 1. The effect of pro-inflammatory cytokines and/or
platelet-rich plasma releasate (PRPr) on gene expression of NP
cell. Expressions were normalized to GAPDH mRNA levels
(controlþ cytokine; NP cell treated with IL-1b and TNF-a,
controlþPRP; NP cell adding to PRPr, cytokinesþPRP [5%,
10%]; NP cell treated with IL-1b and TNF-a for 48h, followed by
PRP [5%, 10%] for 48h, asterisk () indicates p< 0.05 compared
with control, indicates p< 0.05 compared with controlþ cyto-
kines). (a) Collagen type II gene expression, (b) Aggrecan gene
expression, (c) COX-2 gene expression, and (d) MMP-3 gene
expression.
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tissue of herniated IVDs secreted increased levels of
nitric oxide, prostaglandin E2, IL-1, IL-6, IL-8, and
TNF-a.9,10,14 Previous studies showed that IL-1 and
TNF-a are key cytokines mediating matrix degrada-
tion in the IVD.12,14 Even though this study revealed
trends consistent with previous studies, however,
there was no statistical significance in collagen type II,
aggrecan, and MMP-3 changes, except in COX-2 gene
expression. This appears to be because we used human
degenerated NP cells from elderly donors. Lower num-
bers of pro-inflammatory cytokine receptors were found
in the aging NP cells than in young and mature adult
cells.27 Another reason for modest increase of MMP-3
gene expression by the addition of pro-inflammatory
cytokines can be explained by pre-stimulation of degen-
erated disk. The NP cell used in the current study was
obtained from degenerated disk of grade 3 of Thompson
scale, which means that the disk had already been
exposed to pro-inflammatory cytokines related to degen-
eration in vivo. A previous study by Kang et al. is also in
line with this result, showing that addition of IL-1
caused only nonsignificant increase of MMP production
in the degenerated disk, whereas the addition of IL-1
caused the dramatic increase of MMP production in the
nondegenerated disk.10 For these reasons, human NP
cells in our culture model could mask the effect of IL-1b
and TNF-a. Collectively, the current results corroborate
clinical findings regarding the association between pro-
inflammatory cytokines and disk degeneration, and the
NP cell after adding pro-inflammatory cytokines in this
study also represent the in vitro degenerative state of
disks, indicating that the decrease in extracellular
matrix gene expression, mediated by TNF-a and/or IL-1.
Previous studies have reported favorable results
regarding the regenerative potentials of PRP on NP
cells or chondrocytes.20,28 They described consistent
results of increased gene expression of collagen type II
and aggrecan upon PRP addition in both disk cells and
chondrocytes.28,29 The key players in these anabolic
effects are TGF-b and IGF-1.20 The present study
showed only statistically nonsignificant increases in
matrix gene expression after exposure to PRP, com-
pared to the values of control. Given that the NP cell
donors were older than 50-year old, and that TGF-b
and IGF-1 receptors is deplete during the aging
process,30 the results are not contrary to those of
previous studies.20,28 Furthermore, several reports
have insisted that PRP reduces type II collagen mRNA
gene expression as a culture additive.31,32 This effect
is explained by the fact that an increase in prolifera-
tion negatively influences the differentiation status of
a cell.31 Therefore, the current result is not surprising
considering the diametrically opposed reports regard-
ing the effect of PRP on type II collagen and aggrecan
mRNA gene expression.31,32
As previously mentioned, the degenerative disk
state and inflammatory-mimicking environment were
created by adding IL-1b and TNF-a to NP cells in
culture. In this state, the effect of PRP on NP cells
was more pronounced than in the exposure of PRP to
the control group without pro-inflammatory cytokines.
The PRP exposure did not only significantly restore
the down-regulated gene expression of collagen type II
and aggrecan caused by pro-inflammatory cytokines,
but also significantly reduced the increased COX-2
and MMP-3 gene expression. These results imply that
PRP retrieved the pro-inflammatory cytokine-induced
suppression of chondrocyte gene expression and ame-
liorated the increased catabolic and inflammatory
activity represented by MMP-3 and COX-2, respective-
ly. Previous similar reports support the anti-inflamma-
tory role of PRP, and have shown that TGF-b, the
major growth factor in PRP, could counteract the
effects of IL-1, including degradation of type II colla-
gen and proteoglycan produced by chondrocytes.33
Bendinelli et al.26 has determined the anti-inflamma-
tory role of PRP due to the presence of hepatocyte
growth factor (HGF). These results are consistent with
our conclusion that PRP restores a microenvironment
that is beneficial for maintaining NP cell homeostasis
from IL-1 and TNF-a inhibition. From the literature
review, previous studies have focused mainly on the
anabolic effect and/or tissue repair of PRP.16,18,19,28
However, degenerative disk diseases shift toward the
catabolic side when patients require treatment.24
Emphasis should be placed on understanding not only
the anabolic PRP effects, but also the preventive effect
of PRP on catabolic disk degeneration in the environ-
ments related to aging. From this perspective, the
current study firstly elaborates on potential applica-
tions for restoring the anabolic–catabolic imbalance in
degenerative disk disease with aging.
It should be noted that collagen matrix was used as
the frame of the major cartilage matrix for NP cell
culture in the current study. Previous studies have
demonstrated that collagen matrix promoted chondro-
genesis in mesenchymal progenitor cells34 and induced
redifferentiation of articular chondrocytes and NP.20,21,26
Cell–matrix interactions play an important role in
maintaining cartilage homeostasis. The extracellular
matrix can support prime tissue functions and maintain
physical microenvironments of NP cells. According to
previous studies,35,36 cell membrane receptors also play
a crucial role in the cell–matrix interaction. Integrin-a,
-b, and CD44 showed high affinity to collagen fibril and
may facilitate chondrogenesis. In the current study, the
protection efficacy of PRP on chondrogenic-specific gene
expression was enhanced by the assistance of collagen
matrix, which provided a physiological microenviron-
ment beneficial for NP cell survival.
The current study has certain limitations. First, we
should have assessed the plausible mechanism of anti-
inflammatory effects of PRP. However, several previous
studies already suggested that PRP exerts its anti-
inflammatory role in the chondrocyte by inhibiting
nuclear factor kappa B.24,26 Second, the present study
only included NP cells, not AF cells, in response to
PRP. In tissue repair, the anti-inflammatory and
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regenerative effects of PRP seem to be as important in
AF cells as in NP cells. This is because degenerative
annular lesions, such as annular tear, play pivotal
roles in the degeneration cascade of disks.4,15 Further-
more, a previous study reported that the effect of PRP
on matrix synthesis was more pronounced in AF cells
than in NP cells.28 Given that the annulus fibrosus
matrix is rich in collagen, which was used as an
enhancer of the PRP effect, the response of AF cells to
PRP under inflammatory or degenerative environ-
ments should be delineated in future research. Third,
the present study demonstrated only changes in gene
expression after exposure to pro-inflammatory cyto-
kines and/or PRP in the in vitro model. Because the
increased gene expression does not always results in
the increased protein synthesis especially in the elder-
ly,24 this would be a limitation of the current work.
Finally, several recent studies have focused on vari-
ability in the cellular composition of PRP, in which
leukocytes in PRP increased catabolic signaling mole-
cules.37,38 Given the concentration-dependent function
of white blood cells to be either beneficial or harmful
in PRP treatments, the present results should be
considered only based on the cellular characteristics of
current platelet preparations, in that the current PRP
was nonautologous and contained substantial WBC.
In conclusion, the findings of the current study
corroborate our hypothesis that PRP can suppress
cytokine-induced pro-inflammatory degrading enzymes
and mediators. In addition, PRP can rescue gene
expression concerning matrix synthesis, thereby stabi-
lizing NP cell differentiation. Although there have
been several reports suggesting the anti-inflammatory
effect of PRP on chondrocytes, this is the first study
regarding the interaction between human NP cells
with pro-inflammatory cytokines and PRP. Although
additional studies are needed before clinical applica-
tion, the current results encourage further study of
PRP as a conservative, autologous, and feasible treat-
ment for early stage of degenerative disk disease.
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